EMA Wants Stakeholder Input On Regulatory Challenges To 2025
Executive Summary
The EMA has launched a six-month consultation on the challenges facing the agency and the wider EU regulatory network in the face of emerging scientific and technological advances, and has put forward a range of recommendations for action in the period to 2025 to ensure the regulatory system is fit for purpose.
You may also be interested in...
Loud And Clear: EMA Gets Message On Advancing Reg Science
The European Medicines Agency has identified key areas where stakeholders want to see it deliver a real change over the next five years.
EU Getting Left Behind On Drug Review Times
Drug review times in the EU are not getting slower but other agencies are getting faster. A pharmaceutical industry representative offers some frank advice on how the EU can stay competitive.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.